The Next Generation of Immunotherapies - How Do We Manage That?

One of the big challenges has been deaths from overreactive immune systems. Can you describe A, what a cytokine storm is and B, how do we think about managing that for the next generation of immunotherapies? Yeah, it's a good point that you raised. With CD 19 CAR T therapy, there's two broad classes of adverse effects in patients. One is an neurotoxidii mentioned, but the other big one is cytokine release syndrome. And this is basically because you're killing off cells in the body and you're globally wrapping up the immune system. It kind of gets excited, like you said. And it's something that we have to